PATENT CLAIM ANALYSIS

Application Number: 15758083
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-08
Patent Classification: ["514", "259300"]

Abstract:
Certain aspects of the present invention generally relate to compositions and methods for treating a bone disease, for example a genetic bone disease. In one embodiment the bone disease is fibular hemimelia, proximal femoral focal deficiency, tarsal coalition or humeroradial synostosis.

Claim (Index 9):
The method of  claim 7 , wherein the inhibitor \u03b2-catenin signaling is XAV-939.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 90.0
- Lexical Diversity: 1.27778
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15865574', '11026399', '15123030', '15550139', '14389310']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7125327416165246
- 35 USC 102 Novelty (BERT): 0.4987955904153787
- Combined Prediction Score: 0.69115902649641
- Mean Citation Score: 175.595056
- Max Citation Score: 188.64526
- Similarity Product: 127.7523165648198

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test